2023 Fall Clinical Virtual Grand Rounds
2023 Virtual Grand Rounds Session 7: May 24, 2023 - Pediatrics 360: Best Practices and Innovations - Your Questions Answered
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
May 25, 2023
May 25, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Discuss treatment options for psoriasis, atopic dermatitis, acne, rare diseases, infestations, hair and nail conditions with patients
Describe the differences and comparative advantages of therapeutic options for a variety of pediatric dermatologic conditions
Discuss sunscreens, skin care of babies, and management of conditions in skin of color with my patients
Recognize, diagnose, and manage patients with staph, strep, hemangiomas, and vascular lesions
Intended Audience
This activity has been designed for dermatologists, pediatric dermatologists, pediatricians, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
Lawrence Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice-Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego and Rady Children’s Hospital
San Diego, CA
Adelaide Hebert, MD
Professor of Dermatology and Pediatrics
UTHealth McGovern Medical School
Houston, TX
Anthony Mancini, MD
Head, Division of Dermatology
Ann & Robert H. Lurie Children's Hospital of Chicago
Professor of Pediatrics and Dermatology
Northwestern University Feinberg School of Medicine
Chicago, IL
Albert Yan, MD
Professor of Pediatrics and Dermatology
Perelman School of Medicine at the University of Pennsylvania
Emeritus Chief, Pediatric Dermatology
Children’s Hospital of Philadelphia
Philadelphia, PA
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Abbvie, Arcutis, Castle, Dermavant, Galderma, Incyte, Pfizer, Target
Consultant: AbbVie, Almirall, Arena, Aslan, Dermavant, Eli Lilly, Forte, Galderma, Incyte,Krystal, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB and Ortho Derm
Speakers’ Bureau or Honoraria: Leo, Incyte, Pfizer, Regeneron, Sanofi
Ownership Interest: Forte (Board of Directors-options); Verrica: Board of Directors (options)
Grant/Research Support: Pfizer, Arcutis, Lilly, AbbVie
Consultant: Pfizer, Arcutis, Almirall, Biofrontera, Galderma, Or
Speakers’ Bureau or Honoraria: Pfizer, Arcuits, Almirall, Incyte, Sun
has disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
has disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.